Windtree Therapeutics Regains Compliance with Nasdaq
07 Maggio 2024 - 2:00PM
Windtree Therapeutics, Inc. (“Windtree” or the “Company”)
(NasdaqCM: WINT), a biotechnology company focused on advancing
early and late-stage innovative therapies for critical conditions
and diseases, today announced it has received a Bid Price
Compliance Letter from The Nasdaq Stock Market LLC ("Nasdaq")
informing Windtree that it has regained compliance with the minimum
bid price requirement under Nasdaq Listing Rule 5550(a)(2) for
continued listing on The Nasdaq Capital Market.
The Company was previously notified by Nasdaq on January 22,
2024 that it was not in compliance with the minimum bid price rule
because its common stock failed to meet the closing bid price of
$1.00 or more for 30 consecutive trading days, as required by the
Nasdaq Listing Rules. To regain compliance with the Rule, the
Company was required to maintain a minimum closing bid price of
$1.00 or more for at least 10 consecutive trading days. This
requirement was met on May 3, 2024, the tenth consecutive trading
day of the Company’s common stock bid price closing above
$1.00.
About Windtree Therapeutics, Inc.Windtree
Therapeutics, Inc. is a biotechnology company focused on advancing
early and late-stage innovative therapies for critical conditions
and diseases. Windtree’s portfolio of product candidates includes
istaroxime, a Phase II candidate with SERCA2a activating properties
for acute heart failure and associated cardiogenic shock,
preclinical SERCA2a activators for heart failure and preclinical
precision aPKCi inhibitors that are being developed for potential
in rare and broad oncology applications. Windtree also has a
licensing business model with partnership out-licenses currently in
place.
Forward-Looking Statements This press release
contains forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. The Company may,
in some cases, use terms such as “predicts,” “believes,”
“potential,” “proposed,” “continue,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,” “might,” “will,”
“should” or other words that convey uncertainty of future events or
outcomes to identify these forward-looking statements. Such
statements are based on information available to the Company as of
the date of this press release and are subject to numerous
important factors, risks and uncertainties that may cause actual
events or results to differ materially from the Company’s current
expectations. Examples of such risks and uncertainties include,
among other things: the Company’s ability to secure significant
additional capital as and when needed; the Company’s ability to
achieve the intended benefits of the aPKCi asset acquisition with
Varian Biopharmaceuticals, Inc.; the Company’s risks and
uncertainties associated with the success and advancement of the
clinical development programs for istaroxime and the Company’s
other product candidates, including preclinical oncology
candidates; the Company’s ability to access the debt or equity
markets; the Company’s ability to manage costs and execute on its
operational and budget plans; the results, cost and timing of the
Company’s clinical development programs, including any delays to
such clinical trials relating to enrollment or site initiation;
risks related to technology transfers to contract manufacturers and
manufacturing development activities; delays encountered by the
Company, contract manufacturers or suppliers in manufacturing drug
products, drug substances, and other materials on a timely basis
and in sufficient amounts; risks relating to rigorous regulatory
requirements, including that: (i) the U.S. Food and Drug
Administration or other regulatory authorities may not agree with
the Company on matters raised during regulatory reviews, may
require significant additional activities, or may not accept or may
withhold or delay consideration of applications, or may not approve
or may limit approval of the Company’s product candidates, and (ii)
changes in the national or international political and regulatory
environment may make it more difficult to gain regulatory approvals
and risks related to the Company’s efforts to maintain and protect
the patents and licenses related to its product candidates; risks
that the Company may never realize the value of its intangible
assets and have to incur future impairment charges; risks related
to the size and growth potential of the markets for the Company’s
product candidates, and the Company’s ability to service those
markets; the Company’s ability to develop sales and marketing
capabilities, whether alone or with potential future collaborators;
the rate and degree of market acceptance of the Company’s product
candidates, if approved; the economic and social consequences of
the COVID-19 pandemic and the impacts of political unrest,
including as a result of geopolitical tension, including the
conflict between Russia and Ukraine, the People’s Republic of China
and the Republic of China (Taiwan), and the evolving events in
Israel and Gaza, and any sanctions, export controls or other
restrictive actions that may be imposed by the United States and/or
other countries which could have an adverse impact on the Company’s
operations, including through disruption in supply chain or access
to potential international clinical trial sites, and through
disruption, instability and volatility in the global markets, which
could have an adverse impact on the Company’s ability to access the
capital markets. These and other risks are described in the
Company’s periodic reports, including its Annual Report on Form
10-K, Quarterly Reports on Form 10-Q and Current Reports on Form
8-K, filed with or furnished to the Securities and Exchange
Commission and available at www.sec.gov. Any forward-looking
statements that the Company makes in this press release speak only
as of the date of this press release. The Company assumes no
obligation to update forward-looking statements whether as a result
of new information, future events or otherwise, after the date of
this press release.
Contact Information:
Eric Curtisecurtis@windtreetx.com
Grafico Azioni Windtree Therapeutics (NASDAQ:WINT)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Windtree Therapeutics (NASDAQ:WINT)
Storico
Da Dic 2023 a Dic 2024